Table 1 Comparisons of baseline and follow-up characteristics by amyloid-β and white matter hyperintensities status

 Age, years

61.7 (8.3)^a,b,c,d

71.3 (7.7)^b,d

66.7 (7.8)^a,c,d

74.1 (5.0)^b,d

 Female sex, n

94 (67)^b

23 (59)

32 (51)^d

16 (55)

 Education, years

10.9 (3.1)

11.9 (3.3)

11.1 (3.1)

10.3 (2.9)

 Hypertension, n ^e

43 (34)

9 (25)

15 (25)

9 (32)

 Obesity, n ^e

15 (14)

3 (11)

4 (8)

4 (21)

 Diabetes, n ^e

16 (21)

3 (15)

3 (7)

5 (28)

 APOE ε4 allele carrier, n ^e

33 (51)^a

5 (24)^b,c

29 (62)^a

10 (56)^a

 Diagnosis of MCI, n

70 (50)^c

21 (54)^c

40 (64)

22 (76)^a,d

  Amnestic MCI, % within MCI group

40 (57)

15 (71)

27 (68)

17 (77)

  Nonamnestic MCI, % within MCI group

30 (43)

6 (29)

13 (33)

5 (23)

 CSF Aβ_1–42, pg/ml

973.6 (312.0)^b,c

885.0 (242.0)^b,c

404.3 (102.6)^a,d

419.3 (97.2)^a,d

 White matter hyperintensities^f

0.7 (0.5)^a,c

2.3 (0.4)^b,d

0.8 (0.4)^a,c

2.4 (0.5)^b,d

 Follow-up duration, years

2.1 (1.5)

2.2 (1.3)

2.1 (1.2)

2.4 (1.2)

 Time to progression to dementia, years

1.3 (0.5)^a

2.0 (0.7)^d

1.7 (0.7)

2.1 (1.2)

 Progression to dementia, n

8 (6)^a,b,c

9 (23)^d

18 (29)^d

11 (38)^d

  AD-type dementia, n

2 (1)^a,b,c

7 (18)^d

18 (29)^d

10 (35)^d

  Vascular dementia, n

0 (0)

2 (5)

0 (0)

1 (3)

  Frontotemporal dementia, n

4 (3)

0 (0)

0 (0)

0 (0)

  Dementia with Lewy bodies, n

1 (1)

0 (0)

0 (0)

0 (0)

  Dementia with unknown etiology, n

1 (1)

0 (0)

0 (0)

0 (0)